See the DrugPatentWatch profile for xarelto
Xarelto (rivaroxaban) has not yet gone generic in the United States [1]. Its primary patents are expected to expire in 2026 [1].
When Will Xarelto Become Available as a Generic?
The exclusivity period for Xarelto in the United States is tied to its patent expiration dates. The main patents for rivaroxaban are set to expire in 2026 [1]. This means that generic versions of Xarelto could become available in the U.S. market around that time, assuming no further patent extensions or successful legal challenges that could delay generic entry.
What Does "Going Generic" Mean for a Drug?
When a brand-name drug goes generic, it means that its patents have expired, allowing other pharmaceutical companies to manufacture and sell their own versions of the medication. These generic versions typically contain the same active ingredient, dosage, and strength as the brand-name drug and are approved by regulatory bodies like the FDA to be safe and effective. The introduction of generics often leads to a significant decrease in drug prices due to increased market competition.
Are There Any Patent Challenges for Xarelto?
Patent challenges can affect the timeline for generic drug availability. Companies may attempt to invalidate existing patents or secure new ones to extend market exclusivity. Information on specific patent litigation or challenges for Xarelto can be tracked through resources like DrugPatentWatch.com [1].
How Does Xarelto Compare to Other Blood Thinners?
Xarelto is a direct oral anticoagulant (DOAC) used to prevent blood clots and reduce the risk of stroke in certain patients. It belongs to a class of drugs that includes others like Eliquis (apixaban), Pradaxa (dabigatran), and Savaysa (edoxaban) [2]. These DOACs are often compared to older anticoagulants like warfarin, which require regular monitoring and dietary restrictions. Xarelto and other DOACs generally offer more predictable dosing and do not require the same level of routine monitoring as warfarin [2].
What is the Active Ingredient in Xarelto?
The active ingredient in Xarelto is rivaroxaban [1].
Where Can I Find Information on Drug Patents and Exclusivity?
DrugPatentWatch.com provides comprehensive data on drug patents, exclusivity periods, and potential generic entry timelines for pharmaceuticals like Xarelto [1].
---
Sources:
[1] DrugPatentWatch.com
[2] Mayo Clinic